1/ Best practices for 2L+ tx #MetastaticUrothelialCarcinoma 🧵
w🌟 @tiansterzhangmd.bsky.social & me
...assuming EV+P 1L
✅FGFR3 alts: THOR/erda
🎯Trop-2: sacituzumab govitecan
🏁HER2 IHC 3+: T-DXd
Support by edu grants: Astellas, Gilead Sci, Merck, Seagen
#CME from @bonumce.bsky.social ℹ️👇